0000855683 MILESTONE SCIENTIFIC INC. false --12-31 Q1 2022 0.001 0.001 100,000,000 100,000,000 68,153,336 68,153,336 68,120,003 68,120,003 33,333 33,333 10,000 0 2018 2019 2020 450,000 0 3 5 5 25,000 25,000 39,000 34,000 2.8 3.8 5 6 0000855683 2022-01-01 2022-03-31 xbrli:shares 0000855683 2022-05-16 thunderdome:item iso4217:USD 0000855683 2022-03-31 0000855683 2021-12-31 iso4217:USD xbrli:shares 0000855683 2021-01-01 2021-03-31 0000855683 us-gaap:CommonStockMember 2021-12-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000855683 us-gaap:RetainedEarningsMember 2021-12-31 0000855683 us-gaap:NoncontrollingInterestMember 2021-12-31 0000855683 us-gaap:TreasuryStockMember 2021-12-31 0000855683 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000855683 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000855683 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000855683 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0000855683 us-gaap:CommonStockMember 2022-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000855683 us-gaap:RetainedEarningsMember 2022-03-31 0000855683 us-gaap:NoncontrollingInterestMember 2022-03-31 0000855683 us-gaap:TreasuryStockMember 2022-03-31 0000855683 us-gaap:CommonStockMember 2020-12-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000855683 us-gaap:RetainedEarningsMember 2020-12-31 0000855683 us-gaap:NoncontrollingInterestMember 2020-12-31 0000855683 us-gaap:TreasuryStockMember 2020-12-31 0000855683 2020-12-31 0000855683 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000855683 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000855683 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000855683 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000855683 mlss:ConsultantMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000855683 mlss:ConsultantMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000855683 mlss:ConsultantMember us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000855683 mlss:ConsultantMember us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000855683 mlss:ConsultantMember us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000855683 mlss:ConsultantMember 2021-01-01 2021-03-31 0000855683 mlss:BoardOfDirectorsMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000855683 mlss:BoardOfDirectorsMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000855683 mlss:BoardOfDirectorsMember us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000855683 mlss:BoardOfDirectorsMember us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000855683 mlss:BoardOfDirectorsMember us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000855683 mlss:BoardOfDirectorsMember 2021-01-01 2021-03-31 0000855683 us-gaap:CommonStockMember 2021-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000855683 us-gaap:RetainedEarningsMember 2021-03-31 0000855683 us-gaap:NoncontrollingInterestMember 2021-03-31 0000855683 us-gaap:TreasuryStockMember 2021-03-31 0000855683 2021-03-31 xbrli:pure 0000855683 mlss:DentalSegmentMember 2022-03-31 0000855683 mlss:DentalSegmentMember 2021-12-31 0000855683 mlss:MedicalSegmentMember 2022-03-31 0000855683 mlss:MedicalSegmentMember 2021-12-31 0000855683 mlss:SlowMovingMedicalFinishedGoodsMember 2022-03-31 0000855683 mlss:SlowMovingMedicalFinishedGoodsMember 2021-12-31 0000855683 mlss:MilestoneChinaMember 2014-06-30 0000855683 mlss:MilestoneChinaMember mlss:MilestoneBeijingMember 2014-06-30 0000855683 mlss:AnhuiMember 2021-12-31 0000855683 mlss:MilestoneChinaMember mlss:AnhuiMember srt:ChiefExecutiveOfficerMember 2021-10-08 iso4217:CNY 0000855683 mlss:MilestoneChinaMember mlss:AnhuiMember srt:ChiefExecutiveOfficerMember 2021-10-08 2021-10-08 0000855683 mlss:MilestoneChinaMember 2018-12-31 0000855683 mlss:MilestoneChinaMember 2018-01-01 2018-12-31 0000855683 mlss:MilestoneChinaMember 2022-01-01 2022-03-31 0000855683 mlss:AccountsReceivableFromRelatedPartiesMember mlss:MilestoneChinaMember 2022-03-31 0000855683 mlss:MilestoneChinaMember 2021-01-01 2021-03-31 0000855683 mlss:MilestoneChinaMember 2021-12-31 0000855683 mlss:AccountsReceivableFromRelatedPartiesMember mlss:MilestoneChinaMember 2021-12-31 0000855683 mlss:FoundationIntellectualPropertyPatentsMember 2022-03-31 0000855683 mlss:FoundationIntellectualPropertyPatentsMember 2021-12-31 utr:Y 0000855683 us-gaap:PatentsMember srt:MinimumMember 2022-01-01 2022-03-31 0000855683 us-gaap:PatentsMember srt:MaximumMember 2022-01-01 2022-03-31 0000855683 us-gaap:PatentsMember 2022-01-01 2022-03-31 0000855683 us-gaap:PatentsMember 2021-01-01 2021-03-31 0000855683 2021-01-01 2021-12-31 0000855683 mlss:ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember 2022-03-31 0000855683 mlss:ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember 2021-03-31 0000855683 mlss:NonemployeesMember 2022-03-31 0000855683 mlss:NonemployeesMember 2021-03-31 0000855683 us-gaap:EmployeeStockOptionMember mlss:The2020EquityIncentivePlanMember 2022-01-01 2022-03-31 0000855683 us-gaap:EmployeeStockOptionMember mlss:The2020EquityIncentivePlanMember mlss:ViceChairmanOfTheBoardOfDirectorsMember 2021-04-23 2021-04-23 0000855683 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000855683 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000855683 us-gaap:EmployeeStockOptionMember 2022-03-31 0000855683 us-gaap:EmployeeStockOptionMember 2021-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-01-01 2021-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-01 2022-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-03-31 0000855683 us-gaap:RestrictedStockMember 2021-12-31 0000855683 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0000855683 us-gaap:RestrictedStockMember 2022-03-31 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2022-01-01 2022-03-31 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2021-01-01 2021-03-31 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2022-01-01 2022-03-31 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2021-01-01 2021-03-31 0000855683 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000855683 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2022-03-31 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2021-12-31 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2022-03-31 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2021-12-31 0000855683 us-gaap:CorporateNonSegmentMember 2022-03-31 0000855683 us-gaap:CorporateNonSegmentMember 2021-12-31 0000855683 mlss:InstrumentsMember mlss:DentalSegmentMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:InstrumentsMember mlss:MedicalSegmentMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:InstrumentsMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:InstrumentsMember mlss:DentalSegmentMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:InstrumentsMember mlss:MedicalSegmentMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:InstrumentsMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:HandpiecesMember mlss:DentalSegmentMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:HandpiecesMember mlss:MedicalSegmentMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:HandpiecesMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:HandpiecesMember mlss:DentalSegmentMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:HandpiecesMember mlss:MedicalSegmentMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:HandpiecesMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:AccessoriesMember mlss:DentalSegmentMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:AccessoriesMember mlss:MedicalSegmentMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:AccessoriesMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:AccessoriesMember mlss:DentalSegmentMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:AccessoriesMember mlss:MedicalSegmentMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:AccessoriesMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:DentalSegmentMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:MedicalSegmentMember mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:DomesticMember 2022-01-01 2022-03-31 0000855683 mlss:DentalSegmentMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:MedicalSegmentMember mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:DomesticMember 2021-01-01 2021-03-31 0000855683 mlss:InstrumentsMember mlss:DentalSegmentMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:InstrumentsMember mlss:MedicalSegmentMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:InstrumentsMember mlss:DentalSegmentMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:InstrumentsMember mlss:MedicalSegmentMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:HandpiecesMember mlss:DentalSegmentMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:HandpiecesMember mlss:MedicalSegmentMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:HandpiecesMember mlss:DentalSegmentMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:HandpiecesMember mlss:MedicalSegmentMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:AccessoriesMember mlss:DentalSegmentMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:AccessoriesMember mlss:MedicalSegmentMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:AccessoriesMember mlss:DentalSegmentMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:AccessoriesMember mlss:MedicalSegmentMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:DentalSegmentMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:MedicalSegmentMember mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:RestOfWorldMember 2022-01-01 2022-03-31 0000855683 mlss:DentalSegmentMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:MedicalSegmentMember mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:RestOfWorldMember 2021-01-01 2021-03-31 0000855683 mlss:InstrumentsMember mlss:DentalSegmentMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:InstrumentsMember mlss:MedicalSegmentMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:InstrumentsMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:InstrumentsMember mlss:DentalSegmentMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:InstrumentsMember mlss:MedicalSegmentMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:InstrumentsMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:HandpiecesMember mlss:DentalSegmentMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:HandpiecesMember mlss:MedicalSegmentMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:HandpiecesMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:HandpiecesMember mlss:DentalSegmentMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:HandpiecesMember mlss:MedicalSegmentMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:HandpiecesMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:AccessoriesMember mlss:DentalSegmentMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:AccessoriesMember mlss:MedicalSegmentMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:AccessoriesMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:AccessoriesMember mlss:DentalSegmentMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:AccessoriesMember mlss:MedicalSegmentMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:AccessoriesMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:DentalSegmentMember country:CN 2022-01-01 2022-03-31 0000855683 mlss:MedicalSegmentMember country:CN 2022-01-01 2022-03-31 0000855683 country:CN 2022-01-01 2022-03-31 0000855683 mlss:DentalSegmentMember country:CN 2021-01-01 2021-03-31 0000855683 mlss:MedicalSegmentMember country:CN 2021-01-01 2021-03-31 0000855683 country:CN 2021-01-01 2021-03-31 0000855683 mlss:DentalSegmentMember 2022-01-01 2022-03-31 0000855683 mlss:MedicalSegmentMember 2022-01-01 2022-03-31 0000855683 mlss:DentalSegmentMember 2021-01-01 2021-03-31 0000855683 mlss:MedicalSegmentMember 2021-01-01 2021-03-31 0000855683 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorOneMember 2022-01-01 2022-03-31 0000855683 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorTwoMember 2022-01-01 2022-03-31 0000855683 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorThreeMember 2022-01-01 2022-03-31 0000855683 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember mlss:DomesticDistributorMember 2021-01-01 2021-03-31 0000855683 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:CN 2021-01-01 2021-03-31 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorOneMember 2022-01-01 2022-03-31 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorTwoMember 2022-01-01 2022-03-31 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorThreeMember 2022-01-01 2022-03-31 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorFourMember 2022-01-01 2022-03-31 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorOneMember 2021-01-01 2021-12-31 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorTwoMember 2021-01-01 2021-12-31 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember mlss:DistributorThreeMember 2021-01-01 2021-12-31 0000855683 mlss:ManufacturingAgreementForHandpiecesMember 2022-01-01 2022-03-31 0000855683 mlss:ManufacturingAgreementForHandpiecesMember 2021-01-01 2021-03-31 0000855683 mlss:AccountsPayableRelatedPartiesCurrentMember mlss:ManufacturingAgreementForHandpiecesMember 2021-03-31 0000855683 mlss:AccountsPayableRelatedPartiesCurrentMember mlss:ManufacturingAgreementForHandpiecesMember 2021-12-31 0000855683 mlss:ConsultingServicesMember 2022-01-01 2022-03-31 0000855683 mlss:ConsultingServicesMember 2021-01-01 2021-03-31 0000855683 mlss:DirectorOfClinicalAffairsMember 2022-01-01 2022-03-31 0000855683 mlss:DirectorOfClinicalAffairsMember 2021-01-01 2021-03-31 0000855683 mlss:DirectorOfClinicalAffairsMember 2022-03-31 0000855683 mlss:DirectorOfClinicalAffairsMember 2021-12-31 0000855683 mlss:InterimChiefExecutiveOfficerMember 2021-03-02 0000855683 mlss:DirectorClinicalAffairMember 2021-03-01 0000855683 mlss:DirectorClinicalAffairMember 2021-03-02 0000855683 mlss:PreviousPresidentAndChiefExecutiveOfficerMember 2017-07-10 2017-07-10 0000855683 mlss:ConsultantMember 2017-07-10 2017-07-10 0000855683 mlss:ManagingDirectorChinaOperationsMember 2022-01-01 2022-03-31 0000855683 mlss:ManagingDirectorChinaOperationsMember 2021-01-01 2021-03-31 0000855683 mlss:ConsultantMember 2022-01-01 2022-03-31 0000855683 mlss:ConsultantMember 2021-01-01 2021-03-31 0000855683 mlss:PurchaseCommitmentForDevicesMember 2022-01-01 2022-03-31 0000855683 mlss:PurchaseCommitmentForDevicesMember 2022-03-31 0000855683 mlss:PurchaseCommitmentForDevicesMember 2021-12-31 0000855683 mlss:PurchaseCommitmentForEpiduralInstrumentMember 2022-03-31 0000855683 mlss:PurchaseCommitmentForEpiduralInstrumentMember 2021-12-31 0000855683 mlss:OfficeLeaseForHeadquarterInLivingstonNewJerseyMember 2019-08-31 0000855683 srt:MinimumMember mlss:OfficeLeaseForHeadquarterInLivingstonNewJerseyMember 2019-08-01 2019-08-31 0000855683 srt:MaximumMember mlss:OfficeLeaseForHeadquarterInLivingstonNewJerseyMember 2019-08-01 2019-08-31 0000855683 mlss:OfficeLeaseForHeadquarterInLivingstonNewJerseyMember 2019-08-01 2019-08-31 0000855683 2005-01-01 2005-01-01 0000855683 2021-02-25 2021-02-25 0000855683 mlss:LotHC51Member us-gaap:SubsequentEventMember 2022-05-16 0000855683 mlss:LotHC50Member us-gaap:SubsequentEventMember 2022-05-16 0000855683 mlss:LotB210113Member us-gaap:SubsequentEventMember 2022-05-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended March 31, 2022

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-14053

Milestone Scientific Inc.

(Exact name of registrant as specified in its charter)

Delaware | 13-3545623
State or other jurisdiction of Incorporation or organization | (I.R.S. Employer Identification No.)

425 Eagle Rock Avenue Suite 403, Roseland, NJ 07068

(Address of principal executive offices)

Registrant’s telephone number, including area code: 973-535-2717

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Name of each exchange on which registered
Common Stock, par value $.001 per share | NYSE American

Securities registered pursuant to section 12(g) of the Act: NONE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ | Accelerated filer ☐
Non-accelerated filer ☐ | Smaller reporting company ☑
Emerging growth company ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of Exchange on which registered
Common Stock | MLSS | NYSE American

As of May 16, 2022, the registrant has a total of 68,432,335 shares of Common Stock, $0.001 par value outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None

MILESTONE SCIENTIFIC INC.

Form 10-Q

TABLE OF CONTENTS

| PART I—FINANCIAL INFORMATION |
Item 1. | Unaudited Condensed Consolidated Financial Statements | 4
| Balance Sheets as of March 31, 2022 and December 31, 2021 | 4
| Statements of Operations for the three months ended March 31, 2022 and 2021 | 5
| Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2022 and 2021 | 6
| Statements of Cash Flows for the three months ended March 31, 2022 and 2021 | 8
| Notes to Condensed Consolidated Financial Statements | 9
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 24
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 28
Item 4. | Controls and Procedures | 28
| PART II—OTHER INFORMATION |
Item 1. | Legal Proceedings | 28
Item 1A. | Risk Factors | 29
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 30
Item 3. | Defaults Upon Senior Securities | 30
Item 4. | Mine Safety Disclosures | 30
Item 5. | Other Information | 30
Item 6. | Exhibits | 31
Signatures | 32

2

FORWARD-LOOKING STATEMENTS

When used in this Quarterly Report on Form 10-Q, the words “may”, “will”, “should”, “expect”, “believe”, “anticipate”, “continue”, “estimate”, “project”, “intend” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding events, conditions and financial trends that may affect Milestone Scientific’s future plans of operations, business strategy, results of operations and financial condition. Milestone Scientific wishes to ensure that such statements are accompanied by meaningful cautionary statements pursuant to the safe harbor established in the Private Securities Litigation Reform Act of 1995. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Milestone Scientific’s plans and objectives are based, in part, on assumptions involving the continued expansion of its business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Milestone Scientific. Although Milestone Scientific believes that its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate. Considering the significant uncertainties inherent in the forward-looking statements included herein, our history of operating losses that are expected to continue during the ongoing COVID-19 pandemic, the early stage operations of and relative lack of acceptance of our medical products, relying exclusively on two third parties to manufacture our products, changes in our informal manufacturing arrangements made by the manufacturers of our products and disruptions at the manufacturing facilities of our manufacturers exposes us to risks that may harm our business, restrict our operations or require us to relinquish proprietary rights, if physicians do not accept or use our CompuFlo® Epidural Computer Controlled Anesthesia System our ability to generate revenue from sales will be materially impaired, exposure to the risks inherent in international sales and operations, including China, and developments by competitors may render our products or technologies obsolete or non-competitive, the inclusion of such information should not be regarded as a representation by Milestone Scientific or any other person that the objectives and plans of Milestone Scientific will be achieved. Prospective investors are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and the actual results may differ materially from those included within the forward-looking statements as a result of various factors. Such forward-looking statements should, therefore, be considered in light of various important factors, including those set forth herein and others set forth from time to time in Milestone Scientific’s reports, including without limitation, Milestone Scientific's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the “SEC”). Milestone Scientific disclaims any intent or obligation to update such forward-looking statements.

Milestone Scientific is the owner of the following registered U.S. trademarks: CompuDent®; CompuMed®; CompuFlo®; DPS Dynamic Pressure Sensing technology®; Milestone Scientific ®; CathCheckTM; the Milestone logo ®; SafetyWand®; STA Single Tooth Anesthesia Device®; and The Wand ®.

3

Part I- Financial Information

Item 1. Financial Statements

MILESTONE SCIENTIFIC AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

|  | March 31, 2022 |  |  | December 31, 2021 |
ASSETS |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 13,254,775 |  |  | $ | 14,764,346 |
Accounts receivable, net |  |  | 1,063,613 |  |  |  | 943,272 |
Accounts receivable, related party net |  |  | 269,973 |  |  |  | - |
Prepaid expenses and other current assets |  |  | 622,080 |  |  |  | 375,360 |
Inventories, net |  |  | 1,799,908 |  |  |  | 1,541,513 |
Advances on contracts |  |  | 1,217,253 |  |  |  | 1,309,260 |
Total current assets |  |  | 18,227,602 |  |  |  | 18,933,751 |
Furniture, fixtures and equipment, net |  |  | 20,325 |  |  |  | 23,713 |
Intangibles, net |  |  | 264,192 |  |  |  | 277,619 |
Right of use assets |  |  | 528,907 |  |  |  | 550,511 |
Other assets |  |  | 24,150 |  |  |  | 24,150 |
Total assets |  | $ | 19,065,176 |  |  | $ | 19,809,744 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,012,093 |  |  | $ | 780,428 |
Accounts payable, related party |  |  | 1,128,919 |  |  |  | 395,857 |
Accrued expenses and other payables |  |  | 1,335,451 |  |  |  | 1,417,248 |
Accrued expenses, related party |  |  | 257,815 |  |  |  | 414,241 |
Current portion of finance lease liabilities |  |  | 8,743 |  |  |  | 8,545 |
Current portion of operating lease liabilities |  |  | 83,585 |  |  |  | 81,001 |
Total current liabilities |  |  | 3,826,606 |  |  |  | 3,097,320 |
Non-current portion of finance lease liabilities |  |  | 17,801 |  |  |  | 20,062 |
Non-current portion of operating lease liabilities |  |  | 454,857 |  |  |  | 476,980 |
Total liabilities |  | $ | 4,299,264 |  |  | $ | 3,594,362 |
Commitments |  |  |  |  |  |  |  |
Stockholders’ equity |  |  |  |  |  |  |  |
Common stock, par value $.001;authorized 100,000,000 shares; 68,153,336 shares issued at March 31, 2022 and December 31, 2021 and 68,120,003 shares outstanding as March 31, 2022 and December 31, 2021; |  |  | 68,153 |  |  |  | 68,153 |
Additional paid in capital |  |  | 125,385,315 |  |  |  | 124,915,560 |
Accumulated deficit |  |  | (109,605,997 | ) |  |  | (107,704,274 | )
Treasury stock, at cost, 33,333 shares |  |  | (911,516 | ) |  |  | (911,516 | )
Total Milestone Scientific, Inc. stockholders' equity |  |  | 14,935,955 |  |  |  | 16,367,923 |
Noncontrolling interest |  |  | (170,043 | ) |  |  | (152,541 | )
Total stockholders’ equity |  |  | 14,765,912 |  |  |  | 16,215,382 |
Total liabilities and stockholders’ equity |  | $ | 19,065,176 |  |  | $ | 19,809,744 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

4

MILESTONE SCIENTIFIC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

|  | For the three months ended March 31, 2022 |  |  | For the three months ended March 31, 2021 |
Product sales, net |  | $ | 2,700,902 |  |  | $ | 2,924,707 |
Cost of products sold |  |  | 1,018,476 |  |  |  | 1,122,413 |
Gross profit |  |  | 1,682,426 |  |  |  | 1,802,294 |
Selling, general and administrative expenses |  |  | 3,115,629 |  |  |  | 2,749,299 |
Research and development expenses |  |  | 464,466 |  |  |  | 16,444 |
Depreciation and amortization expense |  |  | 16,814 |  |  |  | 20,924 |
Total operating expenses |  |  | 3,596,909 |  |  |  | 2,786,667 |
Loss from operations |  |  | (1,914,483 | ) |  |  | (984,373 | )
Interest expense, net |  |  | (4,742 | ) |  |  | (2,535 | )
Loss before provision for income taxes and net of equity investments |  |  | (1,919,225 | ) |  |  | (986,908 | )
Provision for income taxes |  |  | - |  |  |  | (250 | )
Loss before equity investment |  |  | (1,919,225 | ) |  |  | (987,158 | )
Deferred profit and divesture-equity investment (See Note 6) |  |  | - |  |  |  | 1,301 |
Net loss |  |  | (1,919,225 | ) |  |  | (985,857 | )
Net loss attributable to noncontrolling interests |  |  | (17,502 | ) |  |  | (12,988 | )
Net loss attributable to Milestone Scientific Inc. |  | $ | (1,901,723 | ) |  | $ | (972,869 | )
Net loss per share applicable to common stockholders— |  |  |  |  |  |  |  |
Basic |  |  | (0.03 | ) |  |  | (0.01 | )
Diluted |  |  | (0.03 | ) |  |  | (0.01 | )
Weighted average shares outstanding and to be issued— |  |  |  |  |  |  |  |
Basic |  |  | 69,013,001 |  |  |  | 66,578,435 |
Diluted |  |  | 69,013,001 |  |  |  | 66,578,435 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

5

MILESTONE SCIENTIFIC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

FOR THREE MONTHS ENDED MARCH 31, 2022

(UNAUDITED)

|  | Common Stock Share |  |  | Common Stock Amount |  |  | Additional Paid in Capital |  |  | Accumulated Deficit |  |  | Noncontrolling Interest |  |  | Treasury Stock |  |  | Total Stockholder Equity |
Balance January 1, 2022 |  |  | 68,153,336 |  |  | $ | 68,153 |  |  | $ | 124,915,560 |  |  | $ | (107,704,274 | ) |  | $ | (152,541 | ) |  | $ | (911,516 | ) |  | $ | 16,215,382 |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | 305,370 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 305,370 |
Common stock to be issued to employees for bonuses |  |  | - |  |  |  | - |  |  |  | 164,385 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 164,385 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (1,901,723 | ) |  |  | (17,502 | ) |  |  | - |  |  |  | (1,919,225 | )
Balance March 31, 2022 |  |  | 68,153,336 |  |  | $ | 68,153 |  |  | $ | 125,385,315 |  |  | $ | (109,605,997 | ) |  | $ | (170,043 | ) |  | $ | (911,516 | ) |  | $ | 14,765,912 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

6

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

FOR THREE MONTHS ENDED MARCH 31, 2021

(UNAUDITED)

|  | Common Stock Share |  |  | Common Stock Amount |  |  | Additional Paid in Capital |  |  | Accumulated Deficit |  |  | Noncontrolling Interest |  |  | Treasury Stock |  |  | Total Stockholder Equity |
Balance January 1, 2021 |  |  | 64,171,435 |  |  | $ | 64,171 |  |  | $ | 117,934,696 |  |  | $ | (100,885,957 | ) |  | $ | (94,426 | ) |  | $ | (911,516 | ) |  | $ | 16,106,968 |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | 113,507 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 113,507 |
Common stock issued to employee for compensation expensed in prior periods |  |  | 7,075 |  |  |  | 7 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 7 |
Common stock to be issued for payment of consulting services expensed in prior periods |  |  | 40,010 |  |  |  | 40 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 40 |
Common stock issued to board of directors for services expensed in prior periods |  |  | 18,879 |  |  |  | 18 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 18 |
Common stock issued to employee for stock options exercised |  |  | 435,558 |  |  |  | 436 |  |  |  | 689,754 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 690,190 |
Common stock to be issued to employees for bonuses |  |  | - |  |  |  | - |  |  |  | 100,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 100,000 |
Common stock issued for warrants exercised |  |  | 1,918,925 |  |  |  | 1,919 |  |  |  | 3,010,297 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 3,012,216 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (972,869 | ) |  |  | (12,988 | ) |  |  | - |  |  |  | (985,857 | )
Balance March 31, 2021 |  |  | 66,591,882 |  |  | $ | 66,591 |  |  | $ | 121,848,254 |  |  | $ | (101,858,826 | ) |  | $ | (107,414 | ) |  | $ | (911,516 | ) |  | $ | 19,037,089 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

7

MILESTONE SCIENTIFIC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED

(UNAUDITED)

|  | March 31, 2022 |  |  | March 31, 2021 |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net loss |  | $ | (1,919,225 | ) |  | $ | (985,857 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation expense |  |  | 3,388 |  |  |  | 9,572 |
Amortization of intangibles |  |  | 13,426 |  |  |  | 11,352 |
Stock based compensation |  |  | 305,370 |  |  |  | 113,507 |
Employees paid in stock |  |  | 164,385 |  |  |  | 115,000 |
Non-cash operating lease expense |  |  | (17,378 | ) |  |  | 1,883 |
Deferred profit and divesture-equity investment (See Note 6) |  |  | - |  |  |  | (1,301 | )
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
(Increase) decrease in accounts receivable |  |  | (120,341 | ) |  |  | 101,895 |
(Increase) in accounts receivable, related party |  |  | (269,973 | ) |  |  | (267,300 | )
(Decrease) increase in inventories |  |  | (258,395 | ) |  |  | 399,630 |
Decrease (Increase) in advances on contracts |  |  | 92,007 |  |  |  | (338,995 | )
(Increase) in prepaid expenses and other current assets |  |  | (246,720 | ) |  |  | (272,905 | )
Increase in accounts payable |  |  | 231,668 |  |  |  | 211,072 |
Increase (decrease) in accounts payable, related party |  |  | 733,062 |  |  |  | (200,778 | )
(Decrease) increase in accrued expenses |  |  | (81,797 | ) |  |  | 339,518 |
Decrease in accrued expenses, related party |  |  | (156,427 | ) |  |  | (204,107 | )
Decrease operating right of use lease liability |  |  | 19,442 |  |  |  | - |
Net cash used in operating activities |  | $ | (1,507,508 | ) |  | $ | (967,814 | )
Cash flows from investing activities: |  |  |  |  |  |  |  |
Purchase of furniture, fixtures, and equipment |  |  | - |  |  |  | (5,916 | )
Net cash used in investing activities |  | $ | - |  |  | $ | (5,916 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |
Proceeds from exercise of warrants |  |  | - |  |  |  | 3,012,216 |
Payments finance lease obligations |  |  | (2,063 | ) |  |  | (1,883 | )
Common stock issued to employee for option exercised |  |  | - |  |  |  | 690,190 |
Net cash (used in) provided by financing activities |  | $ | (2,063 | ) |  | $ | 3,700,523 |
Net (decrease) increase in cash and cash equivalents |  |  | (1,509,571 | ) |  |  | 2,726,793 |
Cash and cash equivalents at beginning of period |  |  | 14,764,346 |  |  |  | 14,223,917 |
Cash and cash equivalents at end of period |  | $ | 13,254,775 |  |  | $ | 16,950,710 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

8

MILESTONE SCIENTIFIC, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 — ORGANIZATION AND BUSINESS

All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: CompuDent®; CompuMed®; CompuFlo®; DPS Dynamic Pressure Sensing technology®; Milestone Scientific ®; CathCheckTM; the Milestone logo ®; SafetyWand®; STA Single Tooth Anesthesia System®; and The Wand ®.

Milestone Scientific was incorporated in the State of Delaware in August 1989. Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery device, using The Wand®, a single use disposable handpiece. The device is marketed in dentistry under the trademark CompuDent®, and STA Single Tooth Anesthesia System® and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in 60 other countries. Certain medical devices have obtained CE mark approval and can be marketed and sold in most European countries.

In June 2017, Milestone Scientific received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the CompuFlo® Epidural Computer Controlled Anesthesia System (“Epidural”).We are in the process of meeting with medical facilities and device distributors within the United States, Middle East and Europe. To date there have been seventeen medical devices sold in the United States and limited amounts sold internationally. Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries.

NOTE 2- LIQUIDITY AND UNCERTAINTIES

The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. As of March 31, 2022, the Company had an accumulated deficit of $109.6 million and has incurred a net loss of approximately $1.9 million for the period ended March 31, 2022. Management believes that Milestone Scientific, Inc. will have sufficient cash reserves to meet its anticipated obligations over the next twelve months from the filing date of this quarterly report.

In addition to its employees, the Company relies on (i) distributors, agents, and third-party logistics providers in connection with product sales and distribution and (ii) raw material and component suppliers in the U.S., Europe, and China. If the Company, or any of these entities encounter any disruptions to its or their respective operations or facilities, or if the Company or any of these third-party partners were to shut down for any reason, including by fire, natural disaster, such as a hurricane, tornado or severe storm, power outage, systems failure, labor dispute, pandemic or other public health crises, or other unforeseen disruption, then the Company or they may be prevented or delayed from effectively operating its or their business, respectively.

The coronavirus (COVID-19) adversely impacted the Company's operations, our distributors and suppliers in recent years. In spite of the reopening of dental offices, hospitals, and pain clinics throughout the country and the rest of the world, revenues for three months ended March 31, 2022 and 2021 were adversely affected in particular for the medical business. However, any business interruptions, resulting from COVID-19, or new strain could significantly disrupt our operations and could have a material adverse impact on our business in the future.

In addition, it is uncertain as to what effect the continuing spread of COVID-19 will have on the commercialization efforts of our CompuFlo Epidural and CathCheck systems. Such future developments could have a material adverse effect on the Company financial results and its ability to conduct business as expected.

The Ukrainian-Russian conflict, sanctions imposed by the United States and other western democracies, and any expansion is likely to have unpredictable and wide-ranging effects on the domestic and global economy and financial markets, which could have an adverse effect on our business and results of operations. Already the conflict has caused market volatility, a sharp increase in certain commodity prices, such as wheat and oil, and an increasing number and frequency of cybersecurity threats. So far, we have experienced a decrease in international sales from Ukraine and halted all sales to Russia, a direct impact from the conflict. We will continue to monitor the situation carefully and, if necessary, take action to protect our business, operations and financial condition.

9

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. Principles of Consolidation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in the consolidation.

2. Basis of Presentation

The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with

the instructions for Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present such interim results. Interim results are not necessarily indicative of the results of operations which may be expected for a full year or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2021, included in Milestone Scientific's Annual Report on Form 10-K.

3. Use of Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, stock compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

4. Revenue Recognition

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five steps:

i. | identification of the promised goods or services in the contract;
ii. | determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;
iii. | measurement of the transaction price, including the constraint on variable consideration;
iv. | allocation of the transaction price to the performance obligations based on estimated selling prices; and
v. | recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606.

The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third parties.

Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has no obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.

10

Sales Returns

The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel not consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. In the future, if any of these factors and/or the history of product returns change, adjustments to the allowance for product returns may be required.

Financing and Payment

The Company's payment terms differ by geography and customer, but payment is generally required within 90 days from the date of shipment or delivery.

Disaggregation of Revenue

The Company operates in two operating segments: dental and medical. Therefore, results of the Company operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. See Note 10 for revenues by geographical market, based on the customer’s location, and product category for the three months ended March 31, 2022 and 2021.

5. Variable Interest Entities

A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.

If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Milestone Scientific has completed the VIE analysis relating to Milestone China and Anhui Maishida Medical Technology, Co. Ltd. (“Anhui”).

Milestone Scientific has determined that due to the loss of equity investment in Anhui, the Company no longer has significant influence of Anhui and therefore Anhui is not a variable interest. Milestone Scientific has a variable interest in Milestone China, it considered the guidance in ASC 810, “Consolidation” as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary. Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:

● | Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and
● | Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE

Milestone Scientific does not have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has not been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the CEO of Milestone China who have the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is not the primary beneficiary under ASC 810. Accordingly, Milestone China has not been consolidated into the financial statements of Milestone Scientific and is accounted for under the equity method. See Note 6.

6. Cash and Cash Equivalents

Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, 2022 and December 31, 2021. Milestone Scientific has approximately $12.4 million and $13.9 million, respectively, of investments with short term maturities classified as cash equivalents. At times, such cash, may be more than the Federal Deposit Insurance Corporation insurance limit.

11

7. Accounts Receivable

Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the ability or inability of its customers to make payments on amounts billed. Most credit sales are due within 90 days from invoicing. There have not been any significant credit losses incurred to date. As of March 31, 2022, and December 31, 2021, accounts receivable was recorded, net of allowance for doubtful accounts of $10,000.

8. Inventories

Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or net realizable value. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence, and product expiration requirements.

The valuation allowance creates a new cost basis for the inventory, and it is not subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis.

9. Equity Method Investments

Investments in which Milestone Scientific can exercise significant influence, but do not control, are accounted for under the equity method of accounting and are included in the long-term assets on the unaudited Condensed Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the provision for income tax on the unaudited Condensed Consolidated Statements of Operations. Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments may be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period.

9. Intangible Assets – Patents and Developed Technology

Patents are recorded at cost to prepare and file the applicable documents with the U.S. Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are recorded at acquisition cost and be amortized at the estimated useful life. Patent defense costs, to the extent applicable, are expensed as incurred.

10. Impairment of Long-Lived Assets

Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company’s impairment review process is based upon an estimate of future undiscounted cash flow. Factors the Company considers that could trigger an impairment review include the following:

| • | significant under performance relative to expected historical or projected future operating results,
| • | significant changes in the manner of our use of the acquired assets or the strategy for our overall business
| • | significant negative industry or economic trends
| • | significant technological changes, which would render the technology obsolete

Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.

12

11. Research and Development

Research and development costs, which consist principally of new product development costs payable to third parties, are expensed as incurred. Advance payments for the research are amortized to expense either as services are performed or over the relevant service period using the straight-line method.

12. Income Taxes

Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

At March 31, 2022, and December 31, 2021, we had no uncertain tax positions that required recognition in the unaudited condensed consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the unaudited condensed Consolidated Statements of Operations. No interest and penalties are present for periods open. Tax returns for the 2018, 2019 and 2020 years are subject to audit by federal and state jurisdictions.

13. Basic and Diluted Net Loss Per Common Share

Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, “Earnings per Share”. Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares of 69,013,001 and 66,578,435 for the three months ended March 31, 2022, and 2021 respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants were issued during the period. The Company also includes shares to be issued to employees in the calculation of basic earnings per share because the shares to be issued settle a compensation obligation in a fixed number of shares.

Since Milestone Scientific had net losses in the three months ended March 31, 2022, and 2021, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (“RSA”) and warrants, were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA and warrants totaled 7,543,252 and 6,092,193 on March 31, 2022, and 2021, respectively.

14. Fair Value of Financial Instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required to classify fair value measurements in one of the following categories:

| ● | Level 1 inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.
| ● | Level 2 inputs which are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
| ● | Level 3 inputs are defined as unobservable inputs for the assets or liabilities.

Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. As of March 31, 2022, and December 31, 2021 the Company does not have any assets or liabilities that were measured at fair value on a recurring basis.

15. Stock-Based Compensation

Milestone Scientific accounts for stock-based compensation under ASC Topic 718, Share-Based Payment. ASC Topic 718 requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the unaudited condensed consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values.

13

16. Recent Accounting Pronouncements

In January 2020, FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), which, generally, provides guidance for investments in entities accounted for under the equity method of accounting. ASU 2020-01 is effective for all entities with fiscal years beginning after December 15, 2021, including interim periods therein. The adoption of this standard did not have an impact on the Company's condensed consolidated financial statement.

In August 2020, FASB issued ASU 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity; which, generally, provides guidance for accounting regarding derivatives relating to entities common stock and earnings per share. ASU 2020-06 is effective for all entities with fiscal years beginning after December 15, 2021, including interim periods therein. The adoption of this standard did not have an impact on the Company's consolidated financial statement.

In October 2021, FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with Topic ASC 606, Revenue Recognition from Contracts with Customers (“ASC 606”). To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree’s financial statements. The amendments of ASU 2021-08 are for fiscal years beginning after December 15, 2022, including interim periods. Early adoption is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company will evaluate the impact of ASU 2021-08 on any future business combinations the Company may enter in the future.

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which amends the guidance on measuring credit losses for certain financial assets measured at amortized cost, including trade receivables. The FASB has subsequently issued several updates to the standard, providing additional guidance on certain topics covered by the standard. This update requires entities to recognize an allowance for credit losses using a forward-looking expected loss impairment model, taking into consideration historical experience, current conditions, and supportable forecasts that impact collectability. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic, 326), Derivatives and hedging (Topic 815), and Leases (Topic 842): Effective dates, which deferred the effective date of ASU 2016-13 for the Company. As a result of ASU 2019-10, ASU 2016-13 is effective for all entities with fiscal years beginning after December 15, 2022, including interim periods. The adoption of this update is not expected to have a material impact on the Company's condensed consolidated financial statements.

NOTE 4 — INVENTORIES

Inventories consist of the following:

|  | March 31, 2022 |  |  | December 31, 2021 |
Dental finished goods, net |  | $ | 632,003 |  |  | $ | 342,465 |
Medical finished goods, net |  |  | 989,257 |  |  |  | 1,119,709 |
Component parts and other materials |  |  | 178,648 |  |  |  | 79,339 |
Total inventories |  | $ | 1,799,908 |  |  | $ | 1,541,513 |

The Company maintains an allowance for doubtful accounts on slow moving Medical finished goods of approximately $450,000 as of March 31, 2022 and December 31, 2021.

NOTE 5 — ADVANCES ON CONTRACTS

The advances on contracts represent funding of future STA inventory purchases, epidural instruments, and epidural replacements parts. The balance of the advances as of March 31, 2022, and December 31, 2021 is approximately $1.2 million and $1.3 million, respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.

14

NOTE 6 – INVESTMENT IN AND TRANSACTIONS WITH EQUITY INVESTEES

Milestone China Ltd.

Ownership

In June 2014, Milestone Scientific invested $1 million in Milestone China Ltd. (“Milestone China”), by contributing dental instruments to Milestone China for a 40% ownership interest. Milestone China owns approximately 75% of Milestone Beijing Medical Equipment Company, Ltd (“Milestone Beijing”). At the time, Milestone Beijing had primary responsibility for the sales, marketing, and distribution of the Company’s dental products in China. Milestone Scientific recorded its investment in Milestone China under the equity method of accounting.

In first quarter of 2020, Milestone China and certain manufacturing/marketing affiliates entered into a reorganization agreement (the “Transaction”) pursuant to which Milestone China was to merge into an affiliated manufacturing company, Anhui Maishida Medical Technology, Co. Ltd. (“Anhui”), with Anhui as the surviving entity and to have complete responsibility for sales, marketing, and distribution for the Company’s dental products in China. After completion of the Transaction, Milestone Scientific was expected to have an approximate 28.4% direct ownership in Anhui. Due to the COVID-19 pandemic, the regulatory approval of the planned Transaction was delayed while applicable government offices were closed in China and Hong Kong. Until the completion of the transaction Milestone Scientific's 28.4% in Anhui was held by Milestone China.

On November 23, 2021, management of Milestone Scientific became aware that on October 8, 2021, without approval from Milestone Scientific, (i) Milestone China entered into an Equity Transfer Agreement whereby Milestone China’s 28.4% equity stake in Anhui was transferred to Lidong Zhang, the CEO of Milestone China and Anhui, in exchange for RMB 2,840 million (approximately $440,351) of which no amounts have been or are expected to be received, see below, and (ii) Anhui held a shareholders’ meeting at which the Equity Transfer Agreement was approved by the shareholders of Anhui, eliminating Milestone China’s equity interest in Anhui and Milestone Scientific’s indirect equity interest in Anhui. Based on a review of the minutes of the Anhui shareholders’ meeting, Milestone China was not listed as a shareholder in such meeting due to the executed Equity Transfer Agreement between Lidong Zhang and Milestone China.

Though management believes that this conveyance by Milestone China to LiDong Zhang is outside of the laws of Hong Kong and/or China, as may be applicable, at this juncture Milestone Scientific has no ownership in Anhui and Milestone China has no assets or operations. After considering taking action to assert our rights in the matter, and based on the acknowledgement that such course of action is not without its procedural and substantive challenges in Hong Kong and/or China and, importantly, in view of Michelle Zhang dba Solee Science & Technology USA (“Solee”) (see below), a company located in New Jersey, who became the independent distributor, former agent, for Milestone China and its subsidiaries, and due to the good working relationship developing between Milestone Scientific and Solee and reduction of Milestone Scientific’s credit exposure to a Chinese entity, management is not pursuing any legal action at this time to recover our equity interest.

However, management has determined to pursue an investigation of whether the above-described consideration payable by LiDong Zhang to Milestone China was actually paid to Milestone China and, if so, its recovery. Nevertheless, at this time, Milestone Scientific has not received any consideration, does not know if any of such consideration promised to Milestone China for its interest in Anhui has been paid and, if paid, whether it can recover its share of such consideration. As a result, at this time, Milestone Scientific has not received any consideration and does not know if any of the consideration promised to Milestone China for its interest in Anhui has been paid and, if paid, unless circumstances change, Milestone Scientific does not expect it will receive any of the consideration received by Milestone China for its assets without pursuing legal action. As a result, Milestone Scientific has not recorded a gain or receivable related to the transfer of Anhui. As of March 31, 2022, and December 31, 2021 the investment in Milestone China was zero.

Related Party Transactions

Milestone China Distribution Agreement

Milestone China had been Milestone Scientific’s exclusive distributor in China. During 2017 and prior to the payment default during 2018, Milestone Scientific agreed to sell inventory to Milestone China and its agent. During 2018, Milestone Scientific entered into a payment arrangement with Milestone China to satisfy past due receivables from Milestone China and its agents which amounted to $2.8 million at the time of the payment arrangement. Milestone Scientific collected $950,000 under this arrangement, until Milestone China defaulted on the payment arrangements.

15

For three months ended March 31, 2022, Milestone Scientific shipped handpieces to Solee for the sale to Anhui and recognized revenue of $370,000, of which approximately $270,000 at March 31, 2022 was included in account receivable related party. For the three months ended March 31, 2021, Milestone Scientific shipped instruments and handpieces to Solee for the sale to Anhui and recognized revenue of $506,400. As of December 31, 2021, the Company has approximately $89,000 of deposits from Solee for future shipment of goods included in accrued expenses on the accompanying consolidated balance sheet. As of March 31, 2022, the Company had no deposits from Solee for future shipment of goods included in accrued expenses on the accompanying consolidated balance sheet.

Beginning in mid- November 2021, Milestone Scientific entered into discussions with Michelle Zhang dba Solee Science & Technology USA (“Solee”), a company located in New Jersey, to become Milestone Scientific’s independent distributor for China, the former agent, for Milestone China and its subsidiaries. On November 22, 2021, Wand Dental, Inc., a United States subsidiary of Milestone Scientific, entered into a Buy and Sell Agreement with Solee, pursuant to which Milestone Scientific granted Solee the right to sell Milestone Scientific’s STA instruments, associated handpieces, and spare parts in China to Anhui. As of March 31, 2022 and December 31, 2021, there have been no shipment under the new agreement to Solee.

Gross Profit Deferral

Due to timing differences of when the inventory sold to Milestone China, Anhui or their agent is recognized and when Milestone China and Anhui sells the acquired inventory to third parties, an elimination of the recorded profit is required as of the balance sheet date. In accordance with ASC 323 Investment Equity Method and Joint Ventures, Milestone Scientific has deferred its ownership percentage of the gross profit associated with recognized revenue from sales to Milestone China, Solee as an agent, and Anhui until that product is sold to third parties.

The Company deferred profits on sales to Anhui and Milestone China due to its equity investment in the Companies, pursuant to ASC 323. Investments – Equity Method and Joint Ventures. Due to the Equity Transfer Agreement discussed above, the Company no longer has any equity interest and/or significant influence in Anhui via Milestone China and, as such, all previously deferred profit of $407,000 has been recognized in the accompanying statement of operations at the date of the Equity Transfer Agreement.

At Mach 31, 2022, and December 31, 2021 the deferred profit was approximately $0, which is included in deferred profit, related party in the unaudited condensed consolidated balance sheets. For the three months ended March 31, 2022, and 2021, Milestone Scientific recorded income from gross profit deferral of approximately $0 and $1,301, respectively, in relation to gross profit previously deferred on product sold to Milestone China, Anhui, and Solee recorded as deferred profit and divesture-equity investment on the accompanying unaudited condensed consolidated statement of operations.

NOTE 7 — PATENTS

|  | March 31, 2022 |  |  |  |  |
|  | Cost |  |  | Accumulated Amortization |  |  | Net |
Patents-foundation intellectual property |  | $ | 1,377,863 |  |  | $ | (1,113,671 | ) |  | $ | 264,192 |
Total |  | $ | 1,377,863 |  |  | $ | (1,113,671 | ) |  | $ | 264,192 |

|  | December 31, 2021 |  |  |  |  |
|  | Cost |  |  | Accumulated Amortization |  |  | Net |
Patents-foundation intellectual property |  | $ | 1,377,863 |  |  | $ | (1,100,244 | ) |  | $ | 277,619 |
Total |  | $ | 1,377,863 |  |  | $ | (1,100,244 | ) |  | $ | 277,619 |

Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 to 20 years. Amortization expense was approximately $13,000 and $11,000 for the three months ended March 31, 2022, and March 31, 2021, respectively. The annual amortization expense expected to be recorded for existing intangibles assets for the years 2022 through 2026 and thereafter, is approximately $40,000, $52,000, $34,000, $28,000 and $110,000.

16

NOTE 8— STOCKHOLDERS’ EQUITY

Warrants

The following table summarizes information about shares issuable under warrants outstanding as of March 31, 2022:

|  | Warrant shares outstanding |  |  | Weighted Average exercise price |  |  | Weighted Average remaining life |  |  | Intrinsic value |
Outstanding at January 1, 2022 |  |  | 4,268,221 |  |  |  | 2.18 |  |  |  | 1.50 |  |  | $ | 1,187,546 |
Issued |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Outstanding and exercisable at March 31, 2022 |  |  | 4,268,221 |  |  |  | 2.18 |  |  |  | 1.25 |  |  | $ | 580,142 |

Shares to Be Issued

As of March 31, 2022, and 2021, there were 2,000,127 and 2,264,127 shares respectively, to be issued whose issuance has been deferred to the employees of Milestone Scientific, Inc. respectively.

As of March 31, 2022, and 2021, there were 174,364 and 144,024 shares, respectively, to be issued to non-employees, that will be issued for services rendered. The number of shares was fixed at the date of grant and were fully vested upon grant date.

The following table summarizes information about shares to be issued on March 31, 2022, and 2021, respectively.

|  | March 31, 2022 |  |  | March 31, 2021 |
Shares-to-be-issued, outstanding January 1, 2022 and 2021, respectively |  |  | 2,066,343 |  |  |  | 2,440,878 |
Granted in current period |  |  | 108,148 |  |  |  | 33,238 |
Issued in current period |  |  | - |  |  |  | (65,965 | )
Shares-to be issued outstanding March 31, 2022 and 2021, respectively |  |  | 2,174,491 |  |  |  | 2,408,151 |

Stock Options Plans

The Milestone Scientific Inc. 2020 Equity Compensation Plan, as amended and restated (the "2020 Plan"), provides for awards of restricted common, stock restricted stock units, options to purchase and other awards, up to a maximum 4,000,000 shares of common stock and expires in June 2031. Options may be granted to employees, directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price not less than the fair market value of common stock on the date of grant. In general, options become exercisable over a three-year period from the grant date and expire five years after the date of grant.

On April 8, 2021, as part of its Succession Plan going into effect on April 23, 2021, the Company announced that Leonard Osser, the Interim Chief Executive Officer, would be accepting the role of Vice Chairman of the Board of Directors. As part of accepting this role, he would be granted options to purchase 2,000,000 shares of common stock, exercisable at the fair market value of the common stock on the date of grant, vesting over the five-year period after he steps down as Interim Chief Executive Officer of the Company or ten years from the date of grant, whichever shall end first. The options were issued pursuant to the 2020 Plan.

Milestone Scientific recognizes compensation expense over the requisite service period. For three months ended March 31, 2022 and 2021, Milestone Scientific recognized $305,370, and $113,507 of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations.

As of March 31, 2022 and 2021, there was $3,140,335 and $914,389 of total unrecognized compensation cost related to non- vested options, respectively. Milestone Scientific expects to recognize these costs over a weighted average period of 3.25 and 2.70 for the three months ended of March 31, 2022 and 2021, respectively.

17

A summary of option activity for employees under the plans and changes during the three months ended March 31, 2022 is presented below:

|  | Number of Options |  |  | Weighted Averaged Exercise Price $ |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Options Value $ |
Options outstanding January 1, 2022 |  |  | 2,843,693 |  |  |  | 2.39 |  |  |  | 7.69 |  |  |  | 49,246 |
Granted during 2022 |  |  | 216,296 |  |  |  | 1.52 |  |  |  | 2.98 |  |  |  | - |
Exercised during 2022 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Forfeited or expired during 2022 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options outstanding March 31, 2022 |  |  | 3,059,989 |  |  |  | 2.37 |  |  |  | 7.36 |  |  |  | - |
Exercisable, March 31, 2022 |  |  | 594,914 |  |  |  | 1.98 |  |  |  | 3.80 |  |  |  | - |

The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during three months ended March 31, 2022, risk free interest rate of 2.45%, Volatility of 89.76% (which is based on the Company’s historical over the expected term), expected term 3 years, dividend rate 0% and closing price of the Company’s common stock was $1.52.

A summary of option activity for non-employees under the plans and changes during the three months ended March 31, 2022 presented below:

|  | Number of Options |  |  | Weighted Averaged Exercise Price $ |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Options Value $ |
Options outstanding January 1, 2022 |  |  | 83,330 |  |  |  | 1.85 |  |  |  | 3.33 |  |  |  | 49,748 |
Granted during 2022 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercised during 2022 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options outstanding March 31, 2022 |  |  | 83,330 |  |  |  | 1.85 |  |  |  | 3.08 |  |  |  | 22,585 |
Exercisable, March 31, 2022 |  |  | 63,883 |  |  |  | 1.68 |  |  |  | 2.85 |  |  |  | 22,582 |

For the three months ended March 31, 2022 and 2021, Milestone Scientific recognized approximately $4,978 and $10,329 expense related to non-employee options, respectively.

The information below summarizes the restricted stock award activity for year ended March 31, 2022.

|  | Number of Shares |  |  | Weighted Average Grant-Date Fair Value per Award |
Non-vested as January 1, 2022 |  |  | 96,557 |  |  |  | 2.33 |
Granted |  |  | 75,758 |  |  |  | 1.32 |
Vested |  |  | - |  |  |  |  |
Cancelled |  |  | (41,499 | ) |  |  |  |
Non-vested as March 31, 2022 |  |  | 130,816 |  |  |  | 1.90 |

As of March 31, 2022, there were 130,816 restricted shares granted and deferred under the terms of an employment agreements with the Territory Manager of Milestone Scientific. Such shares will be issued to each party upon completion of 2 years of employment. For the three months ended March 31, 2022, the Company recognized stock compensation expense of approximately $22,000. As of March 31, 2022, the total unrecognized compensation expense was $169,792 related to unvested restricted stock awards, which the Company expects to recognize over an estimated weighted-average period of 1.46 years.

18

NOTE 9 — INCOME TAXES

The utilization of Milestone Scientific's net operating losses may be subject to a substantial limitation due to the "change of ownership provisions" under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a 100% valuation allowance for all its deferred tax assets due to uncertainty as to their future realization.

NOTE 10 — SEGMENT AND GEOGRAPHIC DATA

We conduct our business through two reportable segments: Dental and Medical. These segments offer different products and services to different customer base. The Company provides general corporate services to its segments; however, these services are not considered when making operating decisions and assessing segment performance. These services are reported under “Corporate Services” below and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities and public company compliance.

The following tables present information about our reportable and operating segments:

|  | Three months ended March 31, |
Sales |  |  |  |  |  |  |  |
Net Sales: |  | 2022 |  |  | 2021 |
Dental |  | $ | 2,693,352 |  |  | $ | 2,853,657 |
Medical |  |  | 7,550 |  |  |  | 71,050 |
Total net sales |  | $ | 2,700,902 |  |  | $ | 2,924,707 |

Operating Income (Loss): |  | 2022 |  |  | 2021 |
Dental |  | $ | 354,240 |  |  | $ | 1,126,069 |
Medical |  |  | (1,236,091 | ) |  |  | (895,781 | )
Corporate |  |  | (1,032,632 | ) |  |  | (1,214,661 | )
Total operating loss |  | $ | (1,914,483 | ) |  | $ | (984,373 | )

Depreciation and Amortization: |  | 2022 |  |  | 2021 |
Dental |  | $ | 893 |  |  | $ | 1,706 |
Medical |  |  | 1,019 |  |  |  | 3,851 |
Corporate |  |  | 14,902 |  |  |  | 15,367 |
Total depreciation and amortization |  | $ | 16,814 |  |  | $ | 20,924 |

Income (loss) before taxes and equity in earnings of affiliates: |  | 2022 |  |  | 2021 |
Dental |  | $ | 352,797 |  |  | $ | 1,125,154 |
Medical |  |  | (1,237,540 | ) |  |  | (897,051 | )
Corporate |  |  | (1,034,482 | ) |  |  | (1,215,011 | )
Total loss before taxes and equity in earnings of affiliate |  | $ | (1,919,225 | ) |  | $ | (986,908 | )

Total Assets |  | March 31, 2022 |  |  | December 31, 2021 |
Dental |  | $ | 5,750,344 |  |  | $ | 6,163,169 |
Medical |  |  | 1,301,884 |  |  |  | 1,373,511 |
Corporate |  |  | 12,012,948 |  |  |  | 12,273,064 |
Total assets |  | $ | 19,065,176 |  |  | $ | 19,809,744 |

19

The following table presents information about our operations by geographic area for three months ended March 31, 2022 and 2021. Net sales by geographic area are based on the respective locations of our subsidiaries:

|  | March 31, 2022 |  |  | March 31, 2021 |
Domestic: US |  | Dental |  |  | Medical |  |  | Grand Total |  |  | Dental |  |  | Medical |  |  | Grand Total |
Instruments |  | $ | 122,968 |  |  | $ | - |  |  | $ | 122,968 |  |  | $ | 176,016 |  |  | $ | - |  |  | $ | 176,016 |
Handpieces |  |  | 795,859 |  |  |  | 7,550 |  |  |  | 803,409 |  |  |  | 794,984 |  |  |  | 8,150 |  |  |  | 803,134 |
Accessories |  |  | 24,860 |  |  |  | - |  |  |  | 24,860 |  |  |  | 17,908 |  |  |  | - |  |  |  | 17,908 |
Grand Total |  | $ | 943,687 |  |  | $ | 7,550 |  |  | $ | 951,237 |  |  | $ | 988,908 |  |  | $ | 8,150 |  |  | $ | 997,058 |
International: Rest of World |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Instruments |  | $ | 453,560 |  |  | $ | - |  |  | $ | 453,560 |  |  | $ | 383,255 |  |  | $ | 42,500 |  |  | $ | 425,755 |
Handpieces |  |  | 923,952 |  |  |  | - |  |  |  | 923,952 |  |  |  | 954,534 |  |  |  | 20,400 |  |  |  | 974,934 |
Accessories |  |  | 12,189 |  |  |  | - |  |  |  | 12,189 |  |  |  | 20,560 |  |  |  | - |  |  |  | 20,560 |
Grand Total |  | $ | 1,389,701 |  |  | $ | - |  |  | $ | 1,389,701 |  |  | $ | 1,358,349 |  |  | $ | 62,900 |  |  | $ | 1,421,249 |
International: China |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Instruments |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | 150,000 |  |  | $ | - |  |  | $ | 150,000 |
Handpieces |  |  | 359,964 |  |  |  | - |  |  |  | 359,964 |  |  |  | 356,400 |  |  |  | - |  |  |  | 356,400 |
Accessories |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Grand Total |  | $ | 359,964 |  |  | $ | - |  |  | $ | 359,964 |  |  | $ | 506,400 |  |  | $ | - |  |  | $ | 506,400 |
Total Product Sales |  | $ | 2,693,352 |  |  | $ | 7,550 |  |  | $ | 2,700,902 |  |  | $ | 2,853,657 |  |  | $ | 71,050 |  |  | $ | 2,924,707 |

NOTE 11 -- CONCENTRATIONS

Milestone Scientific has informal arrangements with third-party U.S. manufacturers of the STA, CompuDent and CompuMed devices, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. Consequently, advances on contracts have been classified as current at March 31, 2022 and 2021. The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientific’s ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of termination of such a relationship, would have a material adverse effect on Milestone Scientific’s financial condition, business, and results of operations.

For the three months ended March 31, 2022, an aggregate of approximately 13%, 13%, and 31% of the Company’s net product sales were from three distributors, respectively. For the three months ended March 31, 2021, an aggregate of approximately 29% of the Company’s net product sales were from one domestic distributor, respectively. Additionally, three months ended March 31, 2021 approximately 18% of the Company’s net product sales are to Milestone China.

For the three months ended March 31, 2022, we had the four distributors that accounted for 12%, 18%, 20,% and 21% amount of accounts receivable, respectively. As of December 31, 2021 we had three distributors that accounted for 13%, 28%, and 29% amount of accounts receivable, respectively.

NOTE 12 -- RELATED PARTY TRANSACTIONS

United Systems

Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $1.2 million and $385,000 for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022 and December 31, 2021, Milestone Scientific owed this manufacturer approximately $1.1 million, and $548,000, respectively, which is included in accounts payable, related party and accrued expense, related party on the unaudited condensed consolidated balance sheets.

20

Milestone China

See Note 6 of the notes to the unaudited condensed consolidated financial statements.
Other

In August 2016, K. Tucker Andersen, a significant stockholder of Milestone Scientific, entered into a three-year agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $25,000 for three months ended March 31, 2022, and 2021, respectively.

In August 2016, K. Tucker Andersen, a significant stockholder of Milestone Scientific, entered into a three-year agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $25,000 for each of the three months ended March 31, 2022 and 2021.

The Company engaged Mr. Trombetta as a consultant for a period of twelve months (beginning October 1, 2020, and ending September 30, 2021), to provide international business dental information and business contacts to the Company and provide consulting services for new international business and dental segments. For the three months ended March 31, 2022 and 2021, the Company expensed $0 and $15,000, respectively, for services rendered by Mr. Trombetta. Mr. Trombetta received shares of the Company’s common stock. This agreement was terminated September 30, 2021.

The Director of Clinical Affairs’ royalty fee was approximately $133,000 and $136,000 for three months ended March 31, 2022 and 2021, respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of $39,000 for three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022 and December 31, 2021, Milestone Scientific owed the Director Clinical Affairs for royalties of approximately $133,000 and $123,000, respectively, which is included in accounts payable, related party and accrued expense, related party, in the condensed consolidated balance sheet.

On March 2, 2021, Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company’s then Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Dr. Hochman, and the Company agreed to pay to Mr. Osser, beginning May 9, 2027, half of the royalty (2.5%) on net sales that would otherwise be payable to Dr. Hochman and his wife under their Technology Sale Agreement with the Company, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated February 25, 2021 to reduce from 5% to 2.5% the payments due to them on May 9, 2027 and thereafter, with respect to dental products.

Pursuant to a Succession Agreement dated April 6, 2021 between Mr. Osser and the Company: (i) the Employment Agreement dated as of July 10, 2017 between Mr. Osser and the Company, pursuant to which upon Mr. Osser stepping down as Interim Chief Executive Officer of the Company, the Company agreed to employ him as Managing Director, China Operations of the Company (the “China Operations Agreement”), and (ii) the Consulting Agreement dated as of July 10, 2017 (the “Consulting Agreement”) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation under the China Operations Agreement was modified to reduce the overall compensation by $100,000 to $200,000, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement is increased by $100,000 to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the China Operations Agreement. Compensation under the China Operations Agreement and the Consulting Agreement are payable for 9.5 years from May 19, 2021.

The Company recorded expense of $50,000 and $0 related to the Managing Director, China Operations for three months ended March 31, 2022 and 2021, respectively. The Company recorded expense of $50,000 and $0 related to the US Asian Consulting Group, LLC for three months ended March 31, 2022 and 2021, respectively.

NOTE 13 — COMMITMENTS

(1) Contract Manufacturing Agreement

Milestone Scientific has informal arrangements with third-party manufacturers of the STA, CompuDent® and CompuMed® devices, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. The Company entered a new purchase commitment for the delivery of 3,300 STA CompuDent® instruments. As of March 31, 2022, the purchase order commitment was approximately $2.5 million and advances of approximately $1.1 million are reported in advances on contracts in the consolidated balance sheet. As of December 31, 2021, the purchase order commitment was approximately $2.6 million and advances of approximately $1.3 million are reported in advances on contracts in the consolidated balance sheet.

21

As of March 31, 2022 and December 31, 2021 the company also has advances on an open purchase order for long lead items for a future purchase order for the manufacturing of Epidural instrument of approximately $34,000, respectively. The balance of the advances as of March 31, 2022, and December 31, 2021 is approximately $1.2 million and $1.3 million respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.

(2) Leases

Operating Leases

In August 2019, the Company made the decision to not renew its existing office lease for its corporate headquarters located in Livingston, New Jersey and instead signed a new seven (7) year lease in a new facility located in Roseland, New Jersey (the “Roseland Facility”), which commenced of January 8, 2020. Under the Roseland Facility lease, rent payments commence on April 1, 2020, and the monthly lease payments escalate annually on January 1 of each year, and range from $9,275 to $10,898 per month over the lease term. The Company is also required to pay a fixed electric charge equal to $2.00 per square foot which is paid in equal monthly installments over the lease term or $11,130 annually. These fixed monthly payments have been included in the measurement of the operating lease liability and related operating lease right-of-use asset as the Company has elected the practical expedient to not separate lease and non-lease components for all leases. The Company is also required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises more than new base year amounts, which are accounted for as variable lease expenses.

As of March 31, 2022, total operating lease and finance right-of-use assets were $528,907 and total operating lease and finance liabilities were $538,441, of which $83,585 and $454,857 were classified as current and non-current, respectively. As of March 31, 2022, total finance lease liabilities were $26,544 of which $8,743 and $17,801 were classified as current and non-current, respectively. As of December 31, 2021, total operating lease and finance right-of-use assets were $550,511 and total operating lease and finance liabilities were $577,981, of which $81,001 and $476,980 were classified as current and non-current, respectively. As of December 31, 2021, total finance lease liabilities were $28,607, of which $8,545 and $20,062 were classified as current and non-current, respectively.

The components of lease expense were as follows:

|  | Three Months ended March 31, 2022 |  |  | Three Months ended March 31, 2021 |
Cash paid for operating lease liabilities |  |  | 31,882 |  |  |  | 31,303 |
Cash paid for finance lease liabilities |  |  | 2,685 |  |  |  | 2,685 |
Right-of-use assets obtained in exchange for new operating lease liabilities (1) |  |  | 663,009 |  |  |  |  |
Property and equipment obtained in exchange for new finance lease liabilities |  |  | 43,242 |  |  |  |  |
Weighted Average Remaining Lease Term |  |  |  |  |  |  |  |
Finance leases (years) |  | 2.8 years |  |  |  | 3.8 |
Operating leases (years) |  | 5 years |  |  |  | 6 |

(3) Other Commitments

On March 2, 2021, Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company’s Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Mr. Hochman, and the Company agreed to pay to Mr. Osser, beginning May 9, 2027, half of the royalty (2.5%) on net sales that would otherwise be payable to Mr. Hochman and his wife under the Technology Sale Agreement referred to above, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated February 25, 2021 to reduce from 5% to 2.5% the payments due to them on May 9, 2027 and thereafter, with respect to dental products.

22

NOTE 14— SUBSEQUENT EVENTS

Subsequent to March 31, 2022, due to information identified during the Corrective Action Preventative Action (CAPA) investigation of the Epidural Disposable Kit, Part # 6100-01, lot HC 51 the scope of the voluntary market withdrawal needed to be expanded to include Part # 6100-03, lot HC 50. A new non-conformance was initiated and Lot HC 50 was added to the scope of the CAPA initiated above. The investigation via the CAPA identified that there is an issue with the id adaptors used in both lots HC 51 and HC 50. However, the health hazard evaluation shows that there is no risk to the patient or the user, thus management has determined there are no potential impacts to patients or users. Lots HC 51 and HC 50 are worth approximately $22,000 and $10,000 respectively. Management has not yet determined what the final disposition of the affected inventory will be after the market withdrawal is completed.

Subsequent to March 31, 2022, the Company was notified that some of the Wand STA handpieces, reference # STA—5050-2725, lot B210113 were packaged incorrectly. The Company initiated a Corrective Action Preventative Action (CAPA) investigation to determine the root cause and implement corrective actions. The Health Hazard Evaluation (HHE) was completed and showed that there is no risk to the patient or the user due to this discrepancy, thus management has determined there are no potential impacts to patients or users. However, to provide the highest quality products to the market, Milestone Scientific decided to initiate a voluntary market withdrawal on May 13, 2022. Lot B210113 is worth approximately $25,000. Management has not yet determined what the final disposition of the affected inventory will be after the market withdrawal is completed.

23

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements contained in this report and in connection with management's discussion and analysis and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 31, 2022. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements.

OVERVIEW

Milestone Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and devices for medical, dental and cosmetic use. Since our inception, we have engaged in pioneering proprietary, innovative, computer-controlled injection technologies, and solutions for the medical and dental markets. We believe our technologies are proven and well established. Our common stock was initially listed on the NYSE American on June 1, 2015 and trades under the symbol “MLSS”.

We have focused our resources on redefining the worldwide standard of care for injection techniques by making the experience more comfortable for the patient by reducing the anxiety and stress of receiving injections from the healthcare provider. Our computer-controlled injection devices make injections precise, efficient, and virtually painless.

Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery device, using The Wand®, a single use disposable handpiece. The device is marketed in dentistry under the trademark CompuDent®, and STA Single Tooth Anesthesia System® and is suitable for all dental procedures that require local anesthetic. Our proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices. It regulates flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, used in various dental and medical injections. It has specific medical applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.

Milestone Scientific remains focused on advancing efforts to achieve the following three primary objectives:

● | Establishing Milestone’s DPS Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first time, objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications;

● | Following obtaining successful FDA clearance of our first medical device, Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company; and

● | Expanding our global footprint of our CompuFlo Epidural and CathCheck System by utilizing a direct field sales force and partnering with distribution companies worldwide.

Because of combining the ability to regulate the flow rate and monitor pressure at the tip of the needle, Milestone Scientific developed the industry’s first solution for painlessly administering an intra-ligamentary injection, i.e., “single-tooth anesthesia” which could be used as the only injection necessary for achieving dental anesthesia, foregoing the need to administer traditional injections such as a nerve branch block. In addition to single-tooth anesthesia, the STA System can effectively perform all the traditional injections that dentists routinely give but can provide them virtually pain free and with numerous clinical advantages. This device, which also utilizes a disposable handpiece, is currently marketed by Milestone Scientific as the Wand STA® System.

Milestone Scientific believes its dental devices have set a new standard of care for dental injections. Our dental devices have been used to administer tens of millions of injections worldwide. Each of our devices has a related single use disposable handpiece, leading to a continuing revenue stream following sale of the device. At present, we sell disposable handpieces unique to our legacy product (the Wand and CompuDent) to users who have not upgraded to our current dental product, the Wand STA System.

Building on the success of our proprietary, core technology platform for dental injections, and desiring to pursue other growth opportunities, we have recently begun to expand the uses and applications of our proprietary, patented technologies to achieve greater operational efficiencies, enhanced patient safety and therapeutic adherence, patient satisfaction, and improved quality of care across a broad range of medical specialties. In June 2017, we received FDA regulatory clearance to sell the CompuFlo Epidural Computer Controlled Anesthesia System in the United States for certain medical applications. We intend to continue to expand the uses and applications of our DPS Dynamic Pressure Sensing technology.

24

We believe that we and our technology solutions are widely recognized by key opinion leaders (i.e., academics, anesthesiologists and practicing dentists whose opinions are widely respected), industry experts and medical and dental practitioners as a leader in the emerging, computer-controlled injection industry.

Wand STA Dental Market

Since its market introduction in early 2007, the Wand STA System and prior C-CLAD devices have been used to deliver over 80 million safe, effective, and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.

Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein, Inc. (“Henry Schein”). In June 2016, that agreement was replaced with an exclusive distribution arrangement for our dental products for the United States and Canada with Henry Schein. In December 2020, the exclusive distribution arrangement with Henry Schein was replaced with a non-exclusive distribution arrangement, for distribution in the United States and Canada.

In January 2021, the Company began a process of signing non-exclusive dental distribution arrangements with dental distributors in specific geographical locations in the United States and Canada. To date there are twelve new non-exclusive dental distributors engaged in the United States and Canada. The goal is to add not only additional non-exclusive distributors in the United States, but as well as exploring other co-operation opportunities with Dental Service Organization, education institutions, dental schools and entities in specific dental market segments. To date there are two of such channel partners in the United States.

The goal of changing our marketing plan from a sole exclusive distributor in the USA and Canada, to a large number of non-exclusive distributors is to increase placement of our Wand STA System and thus the expansion of our dental disposables.

On the global front, we have granted exclusive marketing and distribution rights for the Wand STA System to select dental suppliers in various international regions in Asia, Africa, South America, and Europe. They include FM Produkty Dla Stomatologii in Poland and Unident AB in the countries of Denmark, Sweden, Norway, and Iceland. Additionally, the Company is in the process of evaluating current international distributors and adding new distributors, globally as required based on the economics of the region.

The Ukrainian-Russian conflict, sanctions imposed by the United States and other western democracies, and any expansion is likely to have unpredictable and wide-ranging effects on the domestic and global economy and financial markets, which could have an adverse effect on our business and results of operations. Already the conflict has caused market volatility, a sharp increase in certain commodity prices, such as wheat and oil, and an increasing number and frequency of cybersecurity threats. So far, we have experienced a decrease in international sales from Ukraine and halted all sales to Russia, a direct impact from the conflict. We will continue to monitor the situation carefully and, if necessary, take action to protect our business, operations and financial condition.

Medical Market

During 2016, Milestone Scientific filed for 510(k) marketing clearance with the U.S. Food and Drug Administration (FDA) for both intra-articular and epidural injections with the CompuFlo Epidural System. In June 2017, the FDA approved the CompuFlo Epidural System for epidural injections. During the end of the second quarter 2021, Milestone Scientific invested in sales force expansion, thus building up a stronger direct sales force aiming at increasing the adoption and penetration of its technology. At the beginning of the year Milestone Scientific had three sales managers and by July 31, 2021 had established a direct sales force consisting of eleven full time employees covering the US North and Southeast regions along with California. Milestone Scientific continues to partner with distributors for the international markets

In December 2016, we received notification from the FDA that based upon the 510(k)-application submitted for intra-articular injections, we did not adequately document that the device met the equivalency standard required for 510(k) clearances. Following consultation with the FDA Office of Device Evaluation, we intended to file a new 510(k) application for the device in 2019. However, due to financing constraints, a new 510(k) application was not filed in 2019. The Company has decided not to proceed with securing FDA approval for the intra-articular instrument at the present time.

In April 2020, Milestone Scientific, announced that it has validated and integrated the new CathCheck™ feature into the CompuFlo® Epidural System. Using CathCheck, physicians and nurses can now monitor the placement of a catheter to determine the presence or absence of a pulsatile waveform (heartbeat), providing new information that can be used to determine if the catheter is in place or has become dislodged from the epidural space. This can be performed within seconds by measuring the pulsatile waveform within the epidural space.

In March 2022, the Company was notified by a territory manager, that Epidural Disposable Kit, Part # 6100-01, lot HC 51 potentially had an issue. The Company opened an investigation and decided to initiate a voluntary market withdrawal for the Epidural Disposable Kit, Part # 6100-01, lot HC 51. Management has determined that there are no potential impacts to patients or users.

25

The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category:

|  | March 31, 2022 |  |  | March 31, 2021 |
Domestic: US |  | Dental |  |  | Medical |  |  | Grand Total |  |  | Dental |  |  | Medical |  |  | Grand Total |
Instruments |  | $ | 122,968 |  |  | $ | - |  |  | $ | 122,968 |  |  | $ | 176,016 |  |  | $ | - |  |  | $ | 176,016 |
Handpieces |  |  | 795,859 |  |  |  | 7,550 |  |  |  | 803,409 |  |  |  | 794,984 |  |  |  | 8,150 |  |  |  | 803,134 |
Accessories |  |  | 24,860 |  |  |  | - |  |  |  | 24,860 |  |  |  | 17,908 |  |  |  |  |  |  |  | 17,908 |
Grand Total |  | $ | 943,687 |  |  | $ | 7,550 |  |  | $ | 951,237 |  |  | $ | 988,908 |  |  | $ | 8,150 |  |  | $ | 997,058 |
International: Rest of World |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Instruments |  | $ | 453,560 |  |  | $ | - |  |  | $ | 453,560 |  |  | $ | 383,255 |  |  | $ | 42,500 |  |  | $ | 425,755 |
Handpieces |  |  | 923,952 |  |  |  | - |  |  |  | 923,952 |  |  |  | 954,534 |  |  |  | 20,400 |  |  |  | 974,934 |
Accessories |  |  | 12,189 |  |  |  | - |  |  |  | 12,189 |  |  |  | 20,560 |  |  |  |  |  |  |  | 20,560 |
Grand Total |  | $ | 1,389,701 |  |  | $ | - |  |  | $ | 1,389,701 |  |  | $ | 1,358,349 |  |  | $ | 62,900 |  |  | $ | 1,421,249 |
International: China |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Instruments |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | 150,000 |  |  | $ | - |  |  | $ | 150,000 |
Handpieces |  |  | 359,964 |  |  |  | - |  |  |  | 359,964 |  |  |  | 356,400 |  |  |  | - |  |  |  | 356,400 |
Accessories |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Grand Total |  | $ | 359,964 |  |  | $ | - |  |  | $ | 359,964 |  |  | $ | 506,400 |  |  | $ | - |  |  | $ | 506,400 |
Total Product Sales |  | $ | 2,693,352 |  |  | $ | 7,550 |  |  | $ | 2,700,902 |  |  | $ | 2,853,657 |  |  | $ | 71,050 |  |  | $ | 2,924,707 |

Current Product Platform

See Note 1, “Organization and Business”.

Results of Operations

The following table sets forth the consolidated results of operations for the three months ended March 31, 2022 and 2021, respectively. The trends suggested by this table may not be indicative of future operating results:

|  | March 31, 2022 |  |  | March 31, 2021 |
Operating results: |  |  |  |  |  |  |  |
Product sales, net |  | $ | 2,700,902 |  |  | $ | 2,924,707 |
Cost of products sold |  |  | 1,018,476 |  |  |  | 1,122,413 |
Gross profit |  |  | 1,682,426 |  |  |  | 1,802,294 |
Operating expenses: |  |  |  |  |  |  |  |
Selling, general and administrative expenses |  |  | 3,115,629 |  |  |  | 2,749,299 |
Research and development expenses |  |  | 464,466 |  |  |  | 16,444 |
Depreciation and amortization expense |  |  | 16,814 |  |  |  | 20,924 |
Total operating expenses |  |  | 3,596,909 |  |  |  | 2,786,667 |
Loss from operations |  |  | (1,914,483 | ) |  |  | (984,373 | )
Other income, and interest expense net |  |  | (4,742 | ) |  |  | (1,484 | )
Net loss |  |  | (1,919,225 | ) |  |  | (985,857 | )
Net loss attributable to noncontrolling interests |  |  | (17,502 | ) |  |  | (12,988 | )
Net loss attributable to Milestone Scientific Inc. |  |  | (1,901,723 | ) |  |  | (972,869 | )

26

Cash flow: |  | March 31, 2022 |  |  | March 31, 2021 |
Net cash used in operating activities |  | $ | (1,507,508 | ) |  | $ | (967,814 | )
Net cash used in investing activities |  |  | - |  |  |  | (5,916 | )
Net cash (used in) provided by financing activities |  |  | (2,063 | ) |  |  | 3,700,523 |

Three months ended March 31, 2022 compared three months ended March 31, 2021

Net sales for 2022 and 2021 were as follows:

|  | 2022 |  |  | 2021 |  |  | Change |
Dental |  | $ | 2,693,352 |  |  | $ | 2,853,657 |  |  | $ | (160,305 | )
Medical |  |  | 7,550 |  |  |  | 71,050 |  |  | $ | (63,500 | )
Total sales, net |  | $ | 2,700,902 |  |  | $ | 2,924,707 |  |  | $ | (223,805 | )

Consolidated revenue for the three months ended, March 31, 2022, and 2021 were approximately $2.7 million and $2.9 million, respectively. Dental revenue decreased approximately $160,000 for the three months ending March 31, 2022 as compared to the three months ended March 31, 2021. Medical revenue decreased approximately $63,000 for the three months ending March 31, 2022 as compared to the three months ending March 31, 2021. The pandemic had a significant impact on the labor and delivery departments within hospitals, much more so than other departments. This was due to the fact that many pregnant women have opted out of the vaccine, resulting in stricter restrictions than other departments. As a result, our sales team was unable to enter the operatories, which limited our ability to demo and trial the instruments and thus influenced the obtained sales results of the three months ending March 2022.

Gross Profit for 2022 and 2021 were as follows:

|  | 2022 |  |  | 2021 |  |  | Change |
Dental |  | $ | 1,677,661 |  |  | $ | 1,759,682 |  |  | $ | (82,021 | )
Medical |  |  | 4,765 |  |  |  | 42,612 |  |  | $ | (37,847 | )
Total gross profit |  | $ | 1,682,426 |  |  | $ | 1,802,294 |  |  | $ | (119,868 | )

Consolidated gross profit for each of the three months ended March 31, 2022 and 2021 was approximately 62%.

Selling, general and administrative expenses 2022 and 2021 were as follows:

|  | 2022 |  |  | 2021 |  |  | Change |
Dental |  | $ | 866,012 |  |  | $ | 631,882 |  |  | $ | 234,130 |
Medical |  |  | 1,231,886 |  |  |  | 918,098 |  |  |  | 313,788 |
Corporate |  |  | 1,017,731 |  |  |  | 1,199,319 |  |  |  | (181,588 | )
Total selling, general and administrative expenses |  | $ | 3,115,629 |  |  | $ | 2,749,299 |  |  | $ | 366,330 |

Consolidated selling, general and administrative expenses for the three months ended March 31, 2022 and 2021, were approximately $3.1 million, and $2.7 million respectively. The increase of approximately $366,000 is categorized in several areas. Employee salaries, and benefits expenses increased approximately $312,000 during the three months ended March 31, 2022, as the Company hired additional employees to work on the commercialization of the CompuFlo® Epidural System. During the three months ended March 31, 2022, employee travel and other selling, general and administrative expenses increased approximately $145,000 due to the re-opening of dental, and medical offices throughout the country, and the rest of the world. The Company's marketing, professional fees, and warehousing expenses decreased approximately $91,000 for three months ended March 31, 2022.

Research and Development for 2022 and 2021 were as follows:

|  | 2022 |  |  | 2021 |  |  | Change |
Dental |  | $ | 456,516 |  |  | $ | - |  |  | $ | 456,516 |
Medical |  |  | 7,950 |  |  |  | 16,444 |  |  |  | (8,494 | )
Corporate |  |  | - |  |  |  | - |  |  |  | - |
Total research and development |  | $ | 464,466 |  |  | $ | 16,444 |  |  | $ | 448,022 |

27

Consolidated research and development expenses for the three months ended, March 31, 2022 and 2021, were approximately $464,000 and $16,000, respectively. The increase of approximately $448,000 is related to the Company exploring possible enhancements to the STA Single Tooth Anesthesia System product line .

Profit (Loss) from Operations for 2022 and 2021 were as follows:

|  | 2022 |  |  | 2021 |  |  | Change |
Dental |  | $ | 354,240 |  |  | $ | 1,126,069 |  |  | $ | (771,829 | )
Medical |  |  | (1,236,091 | ) |  |  | (895,781 | ) |  |  | (340,310 | )
Corporate |  |  | (1,032,632 | ) |  |  | (1,214,661 | ) |  |  | 182,029 |
Total loss from operations |  | $ | (1,914,483 | ) |  | $ | (984,373 | ) |  | $ | (930,110 | )

The loss from operations was approximately $1.9 million and $1 million for the three months ending March 31, 2022 and 2021, respectively. The increase is related to decrease in revenue and gross profit, the Company incurred additional freight cost due to importing delays from China. and, an increase in selling, general and administrative expenses as discussed above.

Liquidity and Capital Resources

On March 31, 2022, Milestone Scientific had cash and cash equivalents of approximately $13.3 million and working capital of approximately $14.4 million versus working capital of $15.8 million on December 31, 2021. For the three months ended March 31, 2022 and 2021, we had cash flows used in operating activities of approximately $1.5 million and $1 million, respectively. We believe our current cash on hand is sufficient to fund operations through 12 months from filing the unaudited condensed consolidated financial statements.

Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, as well as considering other strategic plans or transactions.

Now that the CompuFlo Epidural System has obtained FDA clearance in the United States (June 2017), the development costs were reduced in 2020, but the selling costs are expected to continue to increase. The FDA clearance has provided the Company with the opportunity to establish distribution in the U.S.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Milestone Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information required by this item.

Item 4. Controls and Procedures

Milestone Scientific’s Chief Executive Officer has evaluated the effectiveness of the design and operation of Milestone Scientific’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone Scientific’s Chief Executive Officer has concluded that our disclosure controls and procedures were not effective as March 31, 2022 due to a previously disclosed material weakness in our internal control over financial reporting, as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

During the quarter ended March 31, 2022, the Company was in the process of remediating the identified material weakness.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

Milestone Scientific is not involved in any material litigation.

28

Item 1A. Risk Factors

The COVID-19 pandemic has and may continue to adversely affect the Company’s business. Additional factors could exacerbate such negative consequences and/or cause other materially adverse effects.

The COVID-19 pandemic did materially adversely affect the Company’s financial results and business operations in the Company’s three months ended March 31, 2022, while economic and health conditions in the United States and across most of the globe have continued to change rapidly due to the Omicron variant since the end of 2021. In the short-term, demand for the Company’s dental products is showing an increase in sell through activity to dental offices. However the change in demand may or may not continue and/or demand may or may not increase from historical levels depending on the duration and severity of the COVID-19 pandemic, the effectiveness of the ongoing vaccination process, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business and manufacturing disruption, inventory shortages, delivery delays, and reduced sales and operations, any of which could materially affect our business, financial condition, and results of operations.

The ability of the Company’s employees to work may be significantly impacted by the Coronavirus.

The Company’s employees are being affected by the COVID-19 pandemic. From time to time, we have had employees working in the office, depending the local positivity rate of COVID-19. As a result of the Omicron variant, beginning in December 2021, most of our office and management personnel were working remotely. As of March 15, 2022 the employees returned in full to the office. The health of the Company’s workforce is of primary concern and the Company may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the coronavirus. Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic, which has required and will continue to require a large investment of time and resources across the entire Company, thereby diverting their attention from other priorities that existed prior to the outbreak of the pandemic. If these conditions worsen, or last for an extended period of time, the Company’s ability to manage its business may be impaired, and operational risks, cybersecurity risks and other risks facing the Company even prior to the pandemic may be elevated.

The COVID-19 pandemic is affecting the Company’s customers, suppliers, vendors, and other business partners, but the Company is not able to assess the full extent of the current impact nor predict the ultimate consequences that will result therefrom.

The full effects of the COVID-19 pandemic are highly uncertain and cannot be predicted.

The COVID-19 pandemic affected the Company’s operations during the three months ended March 31, 2022 and may continue to do so for an indeterminable period thereafter. All of these factors may have far reaching impacts on the Company’s business, operations, and financial results and conditions, directly and indirectly, including without limitation impacts on the health of the Company’s management and employees, manufacturing, distribution, marketing, sales operations, customer, and consumer behaviors, and on the overall economy. The scope and nature of these impacts, most of which are beyond the Company’s control, continue to evolve and the outcomes are uncertain.

Due to the above circumstances and as described generally in this Form 10-Q, the Company’s results of operations for the three-month period ended March 31, 2022 are not necessarily indicative of the results to be expected for the full fiscal year. Management cannot predict the continued impact of the COVID-19 pandemic on the Company’s sales channels, supply chain, manufacturing, and distribution nor to economic conditions generally, including the effects on consumer spending. The ultimate extent of the effects of the COVID-19 pandemic on the Company is highly uncertain and will depend on future developments, and such effects could exist for an extended period of time even after the pandemic might end.

Our business and operations would suffer in the event of cybersecurity or other system failures.

Despite the implementation of security measures, our internal computer systems and those of any third parties with which we partner are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any cybersecurity or system failure, accident or breach to date, if an event were to occur, it could result in a material disruption of our operations, substantial costs to rectify or correct the failure, if possible, and potentially violation of HIPAA and other privacy laws applicable to our operations. If any disruption or security breach resulted in a loss of or damage to our data or applications or inappropriate disclosure of confidential or protected information, we could incur liability, further development of our products could be delayed, and our operations could be disrupted, any of which could severely harm our business and financial condition.

Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.

In general, our success depends upon the quality of our products. Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services, and assuring the safety and efficacy of our products. Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in adverse inspection reports, warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products.

29

Item 2. Unregistered Sales of Equity Securities and use of proceeds

Not applicable.

Item 3. Default upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information

Not applicable.

30

Item 6. Exhibits and Financial Statement Schedules

Exhibit No |  | Description
31.1 |  | Rule 13a-14(a) Certification-Chief Executive Officer*
32.1 |  | Section 1350 Certifications-Chief Executive Officer**
101.INS |  | Inline XBRL Instance Document*
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document*
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document*
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document*
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* | Filed herewith.

** | Furnished herewith and not filed, in accordance with item 601(32) (ii) of Regulation S-K.

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| MILESTONE SCIENTIFIC INC. |
| /s/ Arjan Haverhals |
| Arjan Haverhals |
| Chief Executive Officer |
| Principal Financial Officer |
Date: May 16, 2022 |  |

32